Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics PLC has announced a capital boost through the issuance of Convertible Loan Notes, expecting to secure funding for at least the next 12 months, while also undergoing significant cost-cutting measures and a restructure of its Board. The strategic financial maneuver aims to support the company’s immuno-oncology drug development, with optimism for future licensing deals and commercialization of its pre-clinical portfolio. Leadership changes include Professor Sir Martin Evans transitioning to a Non-Executive Director role, and Dr Michael Stein departing from the Board.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
